People: Strategic Diagnostics Inc. (SDIX.O)
1.44USD
9 Feb 2010
$0.02 (+1.41%)
$1.42
$1.47
$1.47
$1.40
5,495
8,028
$2.25
$0.85
Stave, James
Brief Biography
Mr. James W. Stave is Vice President - Research & Development, Chief Scientific Officer of Strategic Diagnostics Inc. He joined the Company in March 1991 as a research group leader. Subsequently, Dr. Stave was promoted to Director of Research and Development. In October 1993, Dr. Stave was promoted to Vice President—Research and Development and Chief Technical Officer. Dr. Stave was elected Chief Science Officer in 2006. Prior to joining SDI, Dr. Stave worked for DuPont, Molecular Genetics, Inc. and the U.S. Department of Agriculture. Dr. Stave received his Ph.D. in Microbiology from the University of Maryland and his B.S. in Biology from Michigan Technological University.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 236,154 | -- | 67,990 | 326,361 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | 251,900 | 494,590.00 |
| Unexercisable | 24,200 | 6,640.00 |
| Excercised | 5,300 | 9,832.00 |
| Name | Fiscal Year Total |
|---|---|
| DiNuzzo, Francis | 457,891 |
| Bratton, Kevin | -- |
| Stave, James | 326,361 |
| Lindpaintner, Klaus | -- |
| Barbara, Deborah | -- |
| Fronczkowski, Stanley | 349,967 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
